Novel therapeutic targets for allergic airway disease in children

Article Details

Authors
Alessandro Giallongo MD, Giuseppe Fabio Parisi MD, Amelia Licari MD, Giulio Pulvirenti MD, Caterina Cuppari MD, Carmelo Salpietro MD, Gian Luigi Marseglia MD, Salvatore Leonardi MD

Article Type
Review

DOI
10.7573/dic.212590

Related Articles

Article Page

Abstract

The aim of precision medicine is setting up targeted therapies for selected patients that would ideally have high effectiveness and few side effects. This is made possible by targeted therapy drugs that selectively act on a specific pathway. Precision medicine is spreading to many medical specialties, and there is increasing interest in the context of allergic airway diseases, such as allergic rhinitis, chronic rhinosinusitis, and asthma. This review is an update of new targets in the treatment of childhood allergic upper airway diseases and asthma, including the most recent biologic drugs that have already been licensed or are in the pipeline to be tested with children.

Keywords: allergic airway disease, allergic rhinitis, asthma, biologics, children, chronic rhinosinusitis, immunotherapy.

Citation: Giallongo A, Parisi GF, Licari A, Pulvirenti G, Cuppari C, Salpietro C, Marseglia GL, Leonardia S. Novel therapeutic targets for allergic airway disease in children. Drugs in Context 2019; 8: 212590. DOI: 10.7573/dic.212590

Contributions: AL developed the original idea and the final revision, AG and GFP wrote the manuscript, GP and CC revised firstly the manuscript and contributed to English revision and references update, and CS, GLM, and SL made the final analysis and critical revision of the manuscript. All authors read and approved the final manuscript. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at https://www.drugsincontext.com/wp-content/uploads/2019/06/dic.212590-COI.pdf

Acknowledgements: None.

Funding declaration: There was no funding associated with the preparation of this article.

Copyright: Copyright © 2019 Giallongo A, Parisi GF, Licari A, Pulvirenti G, Cuppari C, Salpietro C, Marseglia GL, Leonardia S. https://doi.org/10.7573/dic.212590. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2019 Giallongo A, Parisi GF, Licari A, Pulvirenti G, Cuppari C, Salpietro C, Marseglia GL, Leonardia S. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/novel-therapeutic-targets-for-allergic-airway-disease-in-children/

Correspondence: Prof. Gian Luigi Marseglia, Department of Pediatrics, Foundation IRCCS Policlinico San Matteo, University of Pavia, Viale
Golgi 19, 27100 Pavia, Italy. gl.marseglia@smatteo.pv.it

Provenance: invited; externally peer reviewed.

Submitted: 3 April 2019; Peer review comments to author: 3 May 2019; Revised manuscript received: 30 May 2019; Accepted: 3 June 2019; Publication date: 9 July 2019.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editor-in-Chief gordon.mallarkey@bioexcelpublishing.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF